Published in Oncology on December 13, 2007
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol (2010) 1.44
Diagnosis of hepatocellular carcinoma. World J Gastroenterol (2009) 1.39
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One (2014) 1.09
AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol Genet Metab (2009) 1.03
Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol (2012) 0.96
The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma. BMC Cancer (2015) 0.88
The association of HMGB1 gene with the prognosis of HCC. PLoS One (2014) 0.87
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. Acta Pharmacol Sin (2015) 0.83
MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif. Oncol Lett (2015) 0.81
Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis (2009) 0.80
Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection. Oncotarget (2016) 0.80
CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases. Clin Dev Immunol (2013) 0.77
Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. World J Gastroenterol (2014) 0.76
Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. Cancer Med (2017) 0.75
Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol (2015) 0.75
Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PLoS One (2016) 0.75
Ultrasensitive Luminescent In Vitro Detection for Tumor Markers Based on Inorganic Lanthanide Nano-Bioprobes. Adv Sci (Weinh) (2016) 0.75
Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation. Hepatobiliary Surg Nutr (2016) 0.75
Decreased FOXF1 promotes hepatocellular carcinoma tumorigenesis, invasion, and stemness and is associated with poor clinical outcome. Onco Targets Ther (2016) 0.75
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ (2004) 4.22
NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest (2003) 3.69
A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol (2012) 2.43
Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2002) 2.18
Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology (2014) 2.14
Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology (2006) 1.95
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology (2011) 1.87
Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int (2007) 1.80
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol (2003) 1.79
Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol (2004) 1.77
Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res (2012) 1.67
Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol (2009) 1.66
The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol (2012) 1.63
Clarification required for the definition of hepatitis B virus subgenotypes C1 and C2. Intervirology (2009) 1.60
Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys (2003) 1.56
Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol (2008) 1.55
[Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol (2009) 1.48
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. Liver Int (2010) 1.46
Variability in liver stiffness values from different intercostal spaces. Liver Int (2009) 1.45
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One (2012) 1.43
Colorectal flat neoplasia. Dig Liver Dis (2003) 1.43
N-3 polyunsaturated fatty acid attenuates cholesterol gallstones by suppressing mucin production with a high cholesterol diet in mice. J Gastroenterol Hepatol (2012) 1.41
Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol (2004) 1.39
Influence of pressure change during hydraulic tests on fracture aperture. Ground Water (2012) 1.37
Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int (2005) 1.37
Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer (2008) 1.36
Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci (2008) 1.35
Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol (2008) 1.34
Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology (2007) 1.33
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology (2011) 1.29
Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int (2013) 1.27
Outcome after curative resection for a huge (>or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg (2009) 1.26
HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther (2011) 1.26
Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int (2010) 1.25
MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis (2008) 1.25
Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One (2012) 1.24
MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics (2007) 1.23
Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology (2007) 1.21
Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int (2007) 1.21
Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology (2008) 1.18
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther (2010) 1.18
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol (2010) 1.18
Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol (2009) 1.17
Migration of fibrocytes in fibrogenic liver injury. Am J Pathol (2011) 1.17
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J (2005) 1.17